{"abstract": "The deal, worth up to $632 million, is part of Pfizer\u2019s effort to keep up with rivals that are increasingly relying on biotechnology for products and profits.", "web_url": "https://www.nytimes.com/2011/01/19/health/research/19pfizer.html", "snippet": "The deal, worth up to $632 million, is part of Pfizer\u2019s effort to keep up with rivals that are increasingly relying on biotechnology for products and profits.", "lead_paragraph": " Pfizer, the world\u2019s largest drug company, has agreed to pay up to $632 million to Theraclone Sciences in a research collaboration on antibody drugs for cancer and infectious disease, the companies said Tuesday. ", "source": "The New York Times", "multimedia": [], "headline": {"main": "Pfizer in Deal With Theraclone for Antibody Drug Research", "kicker": null, "content_kicker": null, "print_headline": "Pfizer in Deal With Theraclone for Antibody Drug Research", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "organizations", "value": "Pfizer Inc", "rank": 1, "major": "N"}, {"name": "subject", "value": "Medicine and Health", "rank": 2, "major": "N"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": 3, "major": "N"}, {"name": "subject", "value": "Research", "rank": 4, "major": "N"}], "pub_date": "2011-01-18T22:09:05+0000", "document_type": "article", "news_desk": "Business", "section_name": "Health", "subsection_name": "Research", "byline": {"original": "By Duff Wilson", "person": [{"firstname": "Duff", "middlename": null, "lastname": "Wilson", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/f43363a6-c642-565b-8e82-029047f06595", "word_count": 535, "uri": "nyt://article/f43363a6-c642-565b-8e82-029047f06595"}